Abstracts Archive - Page 51 of 2607 - ACR Meeting Abstracts

Abstract Number: 0870 • ACR Convergence 2025
Same Model, Different Results: Vendor and Microbiome Influence Reproducibility in Collagen Induced Arthritis
Brenda Seymour¹, Brendan Allen² and Kristine Kuhn³, ¹University of Colorado School of Medicine, Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: Although collagen-induced arthritis (CIA) in mice is a useful tool for studying inflammatory arthritis, it is a highly variable model with inconsistent disease severity…
Abstract Number: 0883 • ACR Convergence 2025
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Ali Ayla¹, Chenyue Huang², Claudia Pedroza³, Meng Zhang⁴, John VanBuren⁵, Flavia Castelino⁶, Lorinda Chung⁷, Luke Evnin⁸, Tracy Frech⁹, Jessica Gordon¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹⁰, Dorota Lebiedz-Odrobina⁵, Yiming Luo¹⁴, Ashima Makol¹⁵, Maureen Mayes¹⁶, Zsuzsanna McMahan¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson²⁰, Nora Sandorfi²¹, Ami Shah¹², Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug¹, Virginia Steen²⁴, Elizabeth Volkmann²⁵, Carleigh Zahn¹³, Wenjin J Zheng², Elana Bernstein¹⁴ and Shervin Assassi²⁶, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁴UTHealth Houston Division of Rheumatology, Houston, ⁵University of Utah, Salt Lake City, UT, ⁶Massachusetts General Hospital, Boston, MA, ⁷Stanford University, Stanford, CA, ⁸Scleroderma Research Foundation, Brisbane, CA, ⁹Vanderbilt University Medical Center, Nashville, TN, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Columbia University, New York, NY, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶UT Health Houston Division of Rheumatology, Houston, TX, ¹⁷UT Health Houston, Houston, TX, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern Memorial Hospital, Chicago, IL, ²⁰Northwestern University, Chicago, IL, ²¹University of Pennsylvania, Philadelphia, PA, ²²Duke University, Durham, NC, ²³National Institutes of Health, Great Falls, VA, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable and difficult to predict using clinical variables alone. Therefore, there…
Abstract Number: 0841 • ACR Convergence 2025
Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
Kinga Grzybowski¹ and Irene Tan², ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Lupus Nephritis (LN) is one of the most serious complications of SLE (Systemic Lupus Erythematosus) characterized by an attack of the kidneys by the…
Abstract Number: 0529 • ACR Convergence 2025
Anti-PeptidylArginine Deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Ana-Maria Orbai¹, Hong Wang², Maria Grecu³, Ning Meng⁴, Ji Soo Kim⁵, Clifton Bingham⁴, Uzma Haque², John Miller⁴, Felipe Andrade², Erika Darrah⁶ and Eleni Tiniakou⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³River Hill High School, Clarksville, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Astra Zeneca, Gaithersburg, MD, ⁷UT Health Science Houston, Houston, TX
Background/Purpose: Citrullinated cathelicidin (LL37), a human-derived antimicrobial peptide, is an autoantigen in psoriatic arthritis (PsA).1 LL37 citrullination by peptidylarginine deiminase (PAD) enzymes attenuates immune activation…
Abstract Number: 0513 • ACR Convergence 2025
Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
Massiel Jimenez Artiles¹, asim Khanfar², Pratibha Chaudhary³, Roshan Subedi⁴, Qi Wang⁵ and Anthony Ocon⁶, ¹Rhode Island Hospital, North Providence, RI, ²Rochester Regional Health, Rochester, NY, ³Rochester General Hospital, Rochester, NY, ⁴Medstar Washington Hospital Center, Washington, DC, ⁵Metrohealth System/Case Western Reserve University, Cleveland, OH, ⁶Rochester Regional Health, Fairport, NY
Background/Purpose: While Sjögren’s disease is commonly associated with anti-SSA (anti-Ro) and/or anti-SSB (anti-La) antibodies, these autoantibodies are not disease-specific and may be present in various…
Abstract Number: 0839 • ACR Convergence 2025
Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
Qiuyu Jing¹, Qiang Li², Chiu Wai Shirley Chan³, Weixin Chen⁴, Fung Yu Nick choi⁴, Iris Tang⁵, Chak Sing Lau⁶, Heidi Ling⁶, Jason Wong⁷ and Philip Li², ¹Center for Oncology & Immunology, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ⁶The University of Hong Kong, Hong Kong, Hong Kong, ⁷School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hing Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), lacks reliable non-invasive biomarkers for early detection and monitoring. This study investigates plasma…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Daniel Campos-Martin¹, Nerea Alcorta-Lorenzo², César Antonio Egües Dubuc², Luis Maria Lopez-Dominguez³, Lucia Otero⁴, Fernando Sánchez-Alonso⁵ and Joaquin Maria Belzunegui-Otano⁶, ¹Rheumatology Department, Donostia University Hospital, San Sebastian-Donostia, Pais Vasco, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian-Donostia, Spain
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…
Abstract Number: 0086 • ACR Convergence 2025
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Kiana Chen¹, Chia-Lung Wu², Gulzada Kulzhanova² and Homaira Rahimi³, ¹University of Rochester School of Medicine and Dentistry, Bronx, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 0001 • ACR Convergence 2025
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
Gang Bian¹, Tengteng Li¹, Huiling Liu², Zaoshun Hu², Peng Chen¹, Jay Mei³ and Bing Hou³, ¹Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), ²Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), ³Antengene Corporation, Shanghai, China (People's Republic)
Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
Abstract Number: 0068 • ACR Convergence 2025
Unique Fibroblast-like Synoviocyte Phenotype with Elevated MCSF Expression Induced by TLR5 Activation in Rheumatoid Arthritis
Aryan Patel¹, Osama Al Zoubi² and Shiva Shahrara³, ¹University of Illinois at Chicago, Chicago, ²University of Illinois at Chicago, Chicago, IL, ³University of Illinois, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 1% of the global population, causing significant morbidity and disability. Fibroblast-like synoviocytes (FLS) are…
Abstract Number: 2283 • ACR Convergence 2025
Arrhythmia Risk in Diabetic Rheumatoid Arthritis Patients: Comparative Analysis of IL-6 Inhibitors versus TNF-α Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure², Gurjot Singh³, Kim Nguyen³, Nirys Mateo Faxas⁴, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: Background: Both rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) are independently associated with increased cardiovascular risk, including cardiac arrhythmias. The impact of…
Abstract Number: 0867 • ACR Convergence 2025
NLRP3 Inflammasome Impairs Fracture Repair in Rheumatoid Arthritis through RhoA/Rac1-IL1β Axis-Mediated Suppression of Osteoblast Differentiation
Wen Sun and Hua Wang, Nanjing Medical University, Nanjing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by bone loss and fragility fractures and is a frequent comorbidity. The NLRP3 inflammasome, a key mediator of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].